Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings. Thus, it is important to identify biomarkers for early prediction to increase our understanding of mechanisms underlying DILI that will ultimately aid in the exploration of novel therapeutic strategies to prevent or manage DILI. DILI can be subdivided into 'intrinsic' and 'idiosyncratic' categories, although the validity of this classification remains controversial. Idiosyncratic DILI occurs in a minority of susceptible individuals with a prolonged latency, while intrinsic DILI results from drug-induced direct hepatotoxicity over the course of a few days. The rare occurrence of idiosyncratic DILI requires multicenter collaborative investigations and phenotype standardization. Recent progress in research on idiosyncratic DILI is based on key developments in 3 areas: (1) newly developed high-throughput genotyping across the whole genome allowing for the identification of genetic susceptibility markers, (2) new mechanistic concepts on the pathogenesis of DILI revealing a key role of drug-responsive T lymphocytes in the immunological response, and (3) broad multidisciplinary approaches using different platform "-omics" technologies that have identified novel biomarkers for the prediction of DILI. An association of a specific human leukocyte antigen (HLA) allele with DILI has been reported for several drugs. HLA-restricted T-cell immune responses have also been investigated using lymphocytes and T-cell clones isolated from patients. A microRNA, miR-122, has been discovered as a promising biomarker for the early prediction of DILI. In this review, we summarize recent advances in research on idiosyncratic DILI with an understanding of the key role of adaptive immune systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415 · cited 1×
“Liver-enriched microRNA, miR-122, may be a promising biomarker for the prediction of DILI because it is highly restricted to the liver, detected during the early stages of hepatocellular damage, and well-correlated with histopathologic features.(88) It is a more sensitive biomarker compared to currently used clinical…”
BackgroundDirect, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.
Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., & Pichler, W. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119505 · Cited by 281
Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., & Park, B. K. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp235 · Cited by 223 · cited 1×
“High-mobility group box 1 has been identified as an early serum indicator of hepatocellular necrosis in acute liver injury.(87) Liver-enriched microRNA, miR-122, may be a promising biomarker for the prediction of DILI because it is highly restricted to the liver, detected during the early stages of hepatocellular dama…”
BackgroundWu, Y., Farrell, J., Pirmohamed, M., Park, B. K., & Naisbitt, D. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.12.617 · Cited by 115
Self-citationCallan, H. E., Jenkins, R. E., Maggs, J. L., Lavergne, S. N., Clarke, S. E., Naisbitt, D. J., & Park, B. K. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900034r · Cited by 84
Self-citationThe effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation
Gill, H. J., Tjia, J. F., Kitteringham, N. R., Pirmohamed, M., Back, D. J., & Park, B. K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00007 · Cited by 48
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Teschke, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00730 · Cited by 62
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Brink, A., Pähler, A., Funk, C., Schuler, F., & Schadt, S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.018 · Cited by 42
Metadata
- Authors
- Kim, S.-H., & Naisbitt, D. J.
- Venue
- Allergy, Asthma & Immunology Research
- Publisher
- XMLink
- Published
- 2016
- Volume
- 8
- Issue
- 1
- Pages
- 3
- ISSN
- 2092-7355 (ISSN-L)
- 2092-7363
- OpenAlex
- W1905319828
- Cited by
- 60
- References
- 9
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.